Stock Market Reviews

EDSA (Edesa Biotech, Inc.) News

Get the latest news, insights, and market updates on EDSA (Edesa Biotech, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality
  By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Updated Phase 3 ARDS Results Continue to Show Mortality Benefit On February 24, 2026, Edesa Biotech, Inc. (NASDAQ:EDSA) announced additional Phase 3 results from its paridiprubart (EB05) study in acute respiratory distress syndrome (ARDS) that extend beyond the initial 104-patient cohort that was previously
  Mar 2, 2026 - $EDSA
• Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
  Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisional patent applications for sepsis, acute kidney injury and pneumoniaStrategic collaborations to support late-stage development and commercialization being evaluatedStudy results selected for oral presentation at ATS 2026 conference TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasda
  Feb 24, 2026 - $EDSA
• BC-Most Active Stocks
  Elong Power Holding Ltd. 49,425,228 0.49
  Feb 24, 2026 - $EDSA
• Edesa Biotech Reports Fiscal 1st Quarter 2026 Results
  TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2025 and provided an update on its business. During the first quarter, Edesa progressed manufacturing of its dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), and placebo for an upcoming Phase 2 study i
  Feb 13, 2026 - $EDSA
• EDSA: Gearing Up to Initiate Phase 2 Vitiligo Trial in Mid-2026
  By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Gearing Up for Phase 2 Vitiligo Trial in Mid-2026 Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of EB06, its anti-CXCL10 monoclonal antibody, for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, with
  Dec 15, 2025 - $EDSA
• Edesa Biotech Reports Fiscal Year 2025 Results
  TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2025 and provided an update on its business. During the year, the company initiated manufacturing activities for a Phase 2 study of Edesa’s dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), in patients
  Dec 12, 2025 - $EDSA
• EDSA: EB05 Reduces Risk of Death 25% in Phase 3 ARDS Trial…
  By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Positive Phase 3 Results for EB05 in ARDS On October 28, 2025, Edesa Biotech, Inc. (NASDAQ:EDSA) announced positive results from the Phase 3 trial evaluating paridiprubart (EB05) in the treatment of acute respiratory distress syndrome (ARDS). ARDS is caused by an exaggerated immune response that leads to an
  Nov 5, 2025 - $EDSA
• Edesa Biotech Announces Upcoming Conference Schedule
  TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences: BIO-Europe, Vienna, Austria, November 3-5, 2025LSX Investival Showcase Europe, London, UK, November 17, 2025. Presentation at 3:45 pm GMT. To schedule a meeting with Ed
  Oct 31, 2025 - $EDSA
• Favourable Signals For Edesa Biotech: Numerous Insiders Acquired Stock
  Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
  Oct 28, 2025 - $EDSA
• Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
  Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and recovery Paridiprubart exhibited consistent safety and tolerability profile TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, today announce
  Oct 28, 2025 - $EDSA